参考文献/References:
1 Mazzaferri EL,Robbins RJ,Spencer CA,et al.A consensus report of the role of serum thyroglobublin as a monitoring method for low-risk patients with papillary thyroid carcinoma[J].J Clin Endocrinol Meta,2003,88(4):1433-1441.
2 Girelli ME,De Vido D.Serum thyroglobulin measurements in differentiated thyroid cancer[J].Biomed Pharmacother,2000,54(6):330-333.
3 Pacini F,Fugazzola L,Lippi F,et al.Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses:a clue to the diagnosis of metastatic differentiated thyroid cancer[J].J Clin En-docrinol Metab,1992,74(6):1401-1404.
4 Spencer CA,Takeuchi M,Kazarosyan M.Current status and performance goals for serum thyroglobulin assays[J].Clin Chem,1996,42(1):164-173.
5 Spencer CA,Wang C,Fatemi S,et al.Serum thyroglobulin autoantibodies:Prevalence,influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma[J].J Clin Endocrinol Metab,1998,83(4):1121-1127.
6 Hjiyiannakis P,Mundy J,Harmer C.Thyroglobulin antibodies in differentiated thyroid cancer[J].Clin Oncol,1999,11(4):240-244.
7 Massart C,Maugendre D.Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves’ disease[J].Clin Chem,2002,48(1):102-107.
相似文献/References:
[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[3]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[4]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[5]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[6]邱忠领,罗全勇.甲状腺球蛋白与分化型甲状腺癌[J].国际放射医学核医学杂志,2009,33(2):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
QIU Zhong-ling,LUO Quan-yong.Thyroglobulin and differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):89.[doi:10.3760/cma.j.issn.1673-4114.2009.02.008]
[7]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221.
YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(5):221.
[8]林军,缪蔚冰,吴立坚,等.131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义[J].国际放射医学核医学杂志,2006,30(3):161.
LIN Jun,MIAO Wei-bing,WU Li-jian,et al.The value of thyroglobulin measured and 131I-whole body scan on the differentiated thyroid carcinoma with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):161.
[9]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):79.
[10]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):145.
[11]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]